ZIOPHARM Oncology (NASDAQ:ZIOP) Sets New 12-Month High at $4.98

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $4.98 and last traded at $4.93, with a volume of 148062 shares. The stock had previously closed at $4.43.

A number of equities research analysts have weighed in on ZIOP shares. Laidlaw started coverage on ZIOPHARM Oncology in a research report on Monday, April 1st. They issued a “buy” rating and a $7.50 target price for the company. HC Wainwright restated a “buy” rating and issued a $5.50 target price on shares of ZIOPHARM Oncology in a research report on Thursday, May 9th. BidaskClub upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Zacks Investment Research downgraded ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. Finally, Lake Street Capital started coverage on ZIOPHARM Oncology in a research report on Thursday, April 4th. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $5.75.

The stock has a market capitalization of $874.74 million, a price-to-earnings ratio of -11.23 and a beta of 2.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.89 and a quick ratio of 8.89.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. As a group, research analysts forecast that ZIOPHARM Oncology Inc. will post -0.3 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates lifted its position in ZIOPHARM Oncology by 7.2% in the first quarter. Raymond James & Associates now owns 60,322 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 4,061 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in ZIOPHARM Oncology by 12.3% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,871 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 5,802 shares during the period. Legal & General Group Plc lifted its position in ZIOPHARM Oncology by 30.6% in the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares during the period. SG Americas Securities LLC lifted its position in ZIOPHARM Oncology by 30.8% in the first quarter. SG Americas Securities LLC now owns 31,906 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 7,506 shares during the period. Finally, Northern Trust Corp lifted its position in shares of ZIOPHARM Oncology by 0.5% during the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock valued at $3,081,000 after acquiring an additional 8,068 shares during the last quarter. Hedge funds and other institutional investors own 38.51% of the company’s stock.

WARNING: “ZIOPHARM Oncology (NASDAQ:ZIOP) Sets New 12-Month High at $4.98” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2019/06/14/ziopharm-oncology-nasdaqziop-sets-new-12-month-high-at-4-98.html.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.